Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LDHA | P00338 | 1/20 | 0.48 |
| ▸ | CDK1 | P06493 | 1/20 | 0.47 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.46 |
| ▸ | TLR4 | O00206 | 1/20 | 0.41 |
| ▸ | LY96 | Q9Y6Y9 | 1/20 | 0.41 |
| ▸ | AKT1 | P31749 | 1/20 | 0.41 |
| ▸ | PRKCA | P17252 | 4/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL33763 | 1.00 | LDHA (0.48) | LDHACDK1CCNB1EPHX2TLR4 | |
| SCHEMBL359292 | 1.00 | LDHA (0.48) | LDHACDK1CCNB1EPHX2TLR4 | |
| SCHEMBL359134 | 1.00 | LDHA (0.48) | LDHACDK1CCNB1EPHX2TLR4 | |
| SCHEMBL16253 | 1.00 | LDHA (0.48) | LDHACDK1CCNB1EPHX2TLR4 | |
| SCHEMBL15435964 | 1.00 | LDHA (0.48) | LDHACDK1CCNB1EPHX2TLR4 | |
| SCHEMBL39624 | 1.00 | LDHA (0.48) | LDHACDK1CCNB1EPHX2TLR4 | |
| SCHEMBL313538 | 1.00 | LDHA (0.48) | LDHACDK1CCNB1EPHX2TLR4 | |
| SCHEMBL128339 | 1.00 | LDHA (0.48) | LDHACDK1CCNB1EPHX2TLR4 | |
| SCHEMBL359493 | 1.00 | LDHA (0.48) | LDHACDK1CCNB1EPHX2TLR4 | |
| SCHEMBL271582 | 1.00 | LDHA (0.48) | LDHACDK1CCNB1EPHX2TLR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 829 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260102473-A1 | NOVEL FORMULATIONS | ARECOR LTD (GB) | 2026-04-16 | — | — | US | claimed |
| US-12527845-B2 | Formulations | ARECOR LIMITED (GB) | 2026-01-20 | — | — | US | claimed |
| EP-3773474-B1 | MEDICAL INFUSION PUMP SYSTEM FOR THE DELIVERY OF AN INSULIN COMPOUND | ARECOR LTD (GB) | 2026-01-07 | — | — | EP | claimed |
| US-12512274-B2 | Wet electrolytic capacitor containing a gelled working electrolyte | KYOCERA AVX Components Corporation (US) | 2025-12-30 | — | — | US | claimed |
| US-20250302735-A1 | INJECTION PEN SYSTEM FOR THE DELIVERY OF AN INSULIN COMPOUND | ARECOR LTD (GB) | 2025-10-02 | — | — | US | claimed |
| US-12357562-B2 | Injection pen system for the delivery of an insulin compound | ARECOR LIMITED (GB) | 2025-07-15 | — | — | US | claimed |
| EP-4578035-A1 | WET ELECTROLYTIC CAPACITOR CONTAINING A GELLED WORKING ELECTROLYTE | KYOCERA AVX Components Corporation (US) | 2025-07-02 | — | — | EP | claimed |
| CN-119915880-A | Blood fat dissociating agent and blood fat biosensor | 三诺生物传感股份有限公司 | 2025-05-02 | — | — | CN | claimed |
| CN-119656264-A | Traditional Chinese medicine extracting solution for resisting hyperplasia of mammary glands, and extraction method and application thereof | 广州粉红丝带生物科技有限公司 | 2025-03-21 | — | — | CN | claimed |
| CN-119523949-A | Inflammatory response type drug-loaded microgel system with slow release characteristic | 华中科技大学 | 2025-02-28 | — | — | CN | claimed |
| US-5231087-A | Treatment of skin diseases and tumors with esters and amides of monocarboxylic acids | CELLEGY PHARMACEUTICALS, INC. (US) | 1993-07-27 | — | — | US | claimed |
| US-4962093-A | COMPRISING SUCROSE FATTY ACID ESTERS; LOW ORAL TOXICITY; FOOD ADDITIVES | SS PHARMACUETICAL COMPANY, LTD. (JP) | 1990-10-09 | — | — | US | claimed |
| US-4150114-A | ENHANCED PENETRATION | THE PROCTER & GAMBLE COMPANY (US) | 1979-04-17 | — | — | US | claimed |
| US-4148893-A | SUGAR ESTER AND DIALKYL SULFOXIDE ENHANCE PENETRATION THROUGH SKIN | THE PROCTER & GAMBLE COMPANY (US) | 1979-04-10 | — | — | US | claimed |
| US-4148917-A | PENETRATION | THE PROCTER & GAMBLE COMPANY (US) | 1979-04-10 | — | — | US | claimed |
| US-4148924-A | Dermatological compositions | THE PROCTER & GAMBLE COMPANY (US) | 1979-04-10 | — | — | US | claimed |
| US-4148874-A | ENHANCE PENETRATION OF PHARMOCOLOGICALLY ACTIVE AGENTS THROUGH THE SKIN | THE PROCTER & GAMBLE COMPANY (US) | 1979-04-10 | — | — | US | claimed |
| US-4148887-A | SUGAR ESTER WITH A METHYL SULFOXIDE | THE PROCTER & GAMBLE COMPANY (US) | 1979-04-10 | — | — | US | claimed |
| US-4130643-A | STEROID, SUCROSE ESTER, SULFOXIDE | THE PROCTER & GAMBLE COMPANY (US) | 1978-12-19 | — | — | US | claimed |
| US-4046886-A | SUGAR ESTER, PHOSPHINE OXIDE | THE PROCTER & GAMBLE COMPANY (US) | 1977-09-06 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260102473-A1 | NOVEL FORMULATIONS | IAPP, SLC39A11, SLC30A7 | LDHA 1364/4885CDK1 1715/4885CCNB1 3557/4885 |
| US-12512274-B2 | Wet electrolytic capacitor containing a gelled working electrolyte | DCLK1, DCLK3, SLC9A2 | LDHA 469/4885CDK1 2220/4885CCNB1 4331/4885 |
| US-12527845-B2 | Formulations | IAPP, SLC30A7, GCG | LDHA 1521/4885CDK1 2589/4885CCNB1 3894/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.